Fresenius SE & Co. KGaA Business Summary

Fresenius SE & Co. KGaA is a global healthcare conglomerate that generates revenue through a diversified mix of medical products, hospital operations, and specialized services. Its primary business segments include Fresenius Kabi, which focuses on intravenously administered generic drugs, clinical nutrition, and biosimilars, and Fresenius Helios, the leading private hospital operator in Europe with dominant networks in Germany and Spain. Following the 2023 deconsolidation of its dialysis subsidiary, Fresenius Medical Care (FMC), the company maintains a significant minority stake in the renal care giant while pivoting toward its "FutureFresenius" strategy to optimize its portfolio, including the ongoing transformation of its hospital service arm, Fresenius Vamed. The company competes directly with global peers such as Baxter International, B. Braun, HCA Healthcare, and DaVita, positioning itself as a vertically integrated leader in critical care and private healthcare provision. The company was founded in 1912 by pharmacist Dr. Eduard Fresenius, though its modern expansion was spearheaded by his foster daughter, Else Kröner, whose legacy continues through the Else Kröner-Fresenius-Stiftung, the company's largest shareholder with a 27% stake. The current leadership team is led by CEO Michael Sen, who joined in 2022 after serving as a board member at Siemens AG and CFO of E.ON SE. He is supported by CFO Sara Hennicken, a former Managing Director at Deutsche Bank, and Pierluigi Antonelli, CEO of Fresenius Kabi, who brings extensive pharmaceutical experience from Novartis and Sandoz. Other key executives include Robert Möller, CEO of Fresenius Helios, and Michael Moser, who oversees legal and the Vamed transformation. Notable institutional investors alongside the founding foundation include BlackRock and Vanguard, reflecting the company's status as a core component of the DAX index.